TradingKey

關於 Veracyte Inc 公司

Veracyte, Inc. 是一家全球診斷公司。該公司爲臨牀醫生提供指導和保證患者所需的見解。該公司提供針對甲狀腺癌 (Afirma)、前列腺癌 (Decipher Prostate)、乳腺癌 (Prosigna)、間質性肺病 (Envisia) 和膀胱癌 (Decipher Bladder) 的檢測。其 Percepta 鼻拭子檢測正在其臨牀實驗室改進修正案 (CLIA) 實驗室中進行，以支持臨牀研究，其針對腎癌和淋巴瘤的檢測正在開發中，後者作爲伴隨診斷。其產品包括 Prosigna 乳腺癌檢測、nCounter 分析系統、相關診斷試劑盒和服務。在美國，該公司通過位於加利福尼亞州南舊金山和聖地亞哥的 CLIA 實驗室提供實驗室開發的檢測 (LDT)，並由位於德克薩斯州奧斯汀的細胞病理學專業知識提供支持。該公司還提供全基因組 MRD 平臺，使其能夠進行早期癌症診斷和風險評估。

公司簡介

公司代碼VCYT

公司名稱Veracyte Inc

上市日期Oct 30, 2013

CEOMr. Marc A. Stapley

員工數量824

證券類型Ordinary Share

年結日Oct 30

公司地址6000 Shoreline Court, Suite 300

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編94080

電話16502436300

網址https://www.veracyte.com/

公司代碼VCYT

上市日期Oct 30, 2013

CEOMr. Marc A. Stapley

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Marc A. Stapley

Chief Executive Officer, Director

116.51K

-7.46%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Chairman of the Board

62.45K

+17.55%

Ms. Rebecca Chambers

Chief Financial Officer

33.34K

-13.87%

Dr. Eliav Barr, M.D.

Independent Director

32.81K

+39.68%

Mr. Evan Jones

Independent Director

32.19K

+40.76%

Ms. Muna Bhanji

Independent Director

27.84K

+20.48%

Mr. Jens Holstein

Independent Director

25.73K

+56.82%

Dr. Phillip G. (Phil) Febbo, M.D.

Chief Scientific Officer, Chief Medical Officer

13.09K

-18.41%

Ms. Karin Eastham, CPA

Independent Director

11.76K

+67.35%

Ms. Annie Mcguire

Chief Human Resources Officer, General Counsel

10.19K

-25.60%

名稱

名稱/職務

職務

持股

持股變動

Mr. Marc A. Stapley

Chief Executive Officer, Director

116.51K

-7.46%

Dr. Robert S. (Rob) Epstein, M.D.

Independent Chairman of the Board

62.45K

+17.55%

Ms. Rebecca Chambers

Chief Financial Officer

33.34K

-13.87%

Dr. Eliav Barr, M.D.

Independent Director

32.81K

+39.68%

Mr. Evan Jones

Independent Director

32.19K

+40.76%

Ms. Muna Bhanji

Independent Director

27.84K

+20.48%

收入明細

單位: USD更新時間: 7月6日週日

FY2024

FY2023

FY2022

FY2021

FY2020

暫無數據

地區USD

名稱

營收

佔比

United States

423.54M

95.01%

International

22.23M

4.99%

業務

地區

暫無數據

股東統計

更新時間: 8月2日週六

持股股東

股東類型

持股股東

佔比

The Vanguard Group, Inc.

10.53%

BlackRock Institutional Trust Company, N.A.

7.92%

Fidelity Management & Research Company LLC

7.88%

Artisan Partners Limited Partnership

6.69%

Wellington Management Company, LLP

4.92%

Other

62.06%

持股股東

佔比

The Vanguard Group, Inc.

10.53%

BlackRock Institutional Trust Company, N.A.

7.92%

Fidelity Management & Research Company LLC

7.88%

Artisan Partners Limited Partnership

6.69%

Wellington Management Company, LLP

4.92%

Other

62.06%

股東類型

持股股東

佔比

Investment Advisor

59.74%

Investment Advisor/Hedge Fund

38.69%

Hedge Fund

4.35%

Research Firm

1.79%

Pension Fund

1.28%

Venture Capital

0.97%

Individual Investor

0.59%

Bank and Trust

0.44%

Sovereign Wealth Fund

0.29%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

597

84.71M

108.17%

-889.52K

2025Q1

612

85.86M

109.67%

-679.43K

2024Q4

593

81.64M

104.75%

-2.62M

2024Q3

567

81.88M

106.62%

-2.30M

2024Q2

533

81.65M

106.83%

-3.86M

2024Q1

532

81.30M

103.75%

+1.22M

2023Q4

524

76.49M

104.40%

-3.87M

2023Q3

520

77.05M

105.90%

-3.78M

2023Q2

516

77.28M

106.70%

-4.52M

2023Q1

533

77.62M

107.25%

-6.79M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

The Vanguard Group, Inc.

8.25M

10.53%

+52.03K

+0.64%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

6.21M

7.92%

-41.84K

-0.67%

Mar 31, 2025

Fidelity Management & Research Company LLC

6.17M

7.88%

+4.15M

+205.06%

Mar 31, 2025

Artisan Partners Limited Partnership

5.24M

6.69%

-1.36M

-20.60%

Mar 31, 2025

Wellington Management Company, LLP

3.85M

4.92%

-231.44K

-5.67%

Mar 31, 2025

ARK Investment Management LLC

3.21M

4.09%

-286.15K

-8.20%

May 31, 2025

ArrowMark Colorado Holdings, LLC

3.23M

4.12%

+146.65K

+4.76%

Mar 31, 2025

State Street Global Advisors (US)

3.16M

4.03%

+247.55K

+8.50%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

2.91M

3.72%

+28.17K

+0.98%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.93M

2.47%

+94.91K

+5.16%

Mar 31, 2025

持股ETF

更新時間: 8月2日週六

機構名稱

佔比

ARK Genomic Revolution ETF

3.09%

First Trust NYSE Arca Biotechnology Index Fund

2.67%

Global X Genomics & Biotechnology ETF

2.67%

Invesco Biotechnology & Genome ETF

2.57%

WisdomTree BioRevolution Fund

1.69%

ROBO Global Healthcare Technology & Innovation ETF

1.42%

ROBO Global Artificial Intelligence ETF

1.24%

ARK Innovation ETF

0.98%

Franklin Genomic Advancements ETF

0.88%

SPDR S&P Biotech ETF

0.74%

ARK Genomic Revolution ETF

佔比3.09%

First Trust NYSE Arca Biotechnology Index Fund

佔比2.67%

Global X Genomics & Biotechnology ETF

佔比2.67%

Invesco Biotechnology & Genome ETF

佔比2.57%

WisdomTree BioRevolution Fund

佔比1.69%

ROBO Global Healthcare Technology & Innovation ETF

佔比1.42%

ROBO Global Artificial Intelligence ETF

佔比1.24%

ARK Innovation ETF

佔比0.98%

Franklin Genomic Advancements ETF

佔比0.88%

SPDR S&P Biotech ETF

佔比0.74%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Veracyte Inc

23.640USD

Veracyte Inc

23.640

概覽

公司

財務